NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

X4 Pharmaceuticals, Inc. (XFOR) Stock Analysis

X4 Pharmaceuticals, Inc. (XFOR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

XFOR

$4.04

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XFOR with… →

XFOR Key Statistics

As of Sep 4, 2026
Trading
Open
$4.01
Previous Close
$4.04
Day's Range
4.00–4.08
52-Week Range
2.80–4.83
Volume
168.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.40
Valuation
Market Cap
$400.55M
P/E Ratio
2.83
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
25.28
EPS (ttm)Profit attributable to each share over the last twelve months.
1.43
Financials (FY)
Revenue (FY)
$35.11M+1273.21%
Net Income (FY)
−$79.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
99.15M
1-Year Return
+10.99%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
771.27K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XFOR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.00%
2025−81.83%
2024−12.51%
2023−15.51%
2022−56.64%
2021−64.39%
2020−39.91%
2019−23.13%
2018−81.82%
2017 (partial year)−9.05%

As of September 4, 2026.

XFOR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$35.11M−$79.20M−225.6%
2024$2.56M−$37.45M−1464.6%
2023$0.00−$101.17M—
2022$0.00−$93.87M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$35.11M$29.36M−$86.88M−$79.20M−225.6%
2024$2.56M$1.76M−$141.40M−$37.45M−1464.6%
2023$0.00$0.00−$107.52M−$101.17M—
2022$0.00$0.00−$88.08M−$93.87M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XFOR Valuation vs Biotechnology Median

Median of 656 stocks
MetricXFORBiotechnology medianvs median
P/E2.8312.570.2x the median
P/S ratio25.2815.2666% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values X4 Pharmaceuticals, Inc. (XFOR) at $400.55M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 45 employees.

XFOR last closed at $4.04 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $2.80 to $4.83. The latest close sits 44.29% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $35.11M. Against the prior fiscal year total of $2.56M, that is a change of +1,273.21%. The same year closed with a net loss of $79.20M. The reported profit margin is 0%. Trailing earnings per share are 1.43.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $35.11M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 2.83. That is 0.2 times the Biotechnology median of 12.57. Measured against sales, the shares trade at 25.28 times revenue. On price-to-sales that is 65.6% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.4. Annualized volatility over the trailing 8 years is 138.47%. The trailing one-year price return is +10.99%. Measured over 5 years, that is −51.83% a year compounded.

Growth & Income

The record shows no dividend for XFOR.

So far in 2026 the price is +1.00%. The strongest complete calendar year on file is 2024 at −12.51%; the weakest is 2025 at −81.83%. Of the 8 complete calendar years on file, 0 finished higher.

Peer Comparison

X4 Pharmaceuticals, Inc. (XFOR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
X4 Pharmaceuticals, Inc. XFOR $400.55M 2.8
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. X4 Pharmaceuticals, Inc. trades at a P/E of 2.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Visit website →